WO2005040828A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) Download PDF

Info

Publication number
WO2005040828A3
WO2005040828A3 PCT/EP2004/011404 EP2004011404W WO2005040828A3 WO 2005040828 A3 WO2005040828 A3 WO 2005040828A3 EP 2004011404 W EP2004011404 W EP 2004011404W WO 2005040828 A3 WO2005040828 A3 WO 2005040828A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
gpr49
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/011404
Other languages
French (fr)
Other versions
WO2005040828A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005040828A2 publication Critical patent/WO2005040828A2/en
Publication of WO2005040828A3 publication Critical patent/WO2005040828A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human GPR64 which is associated with the cardiovascular disorders, dermatological disorders, hematological disorders, respiratory diseases, inflammatory diseases, gastroenterological and liver diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, hematological disorders, respiratory diseases, inflammatory diseases, gastroenterological and liver diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR64 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/011404 2003-10-24 2004-10-12 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) WO2005040828A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03024485 2003-10-24
EP03024485.9 2003-10-24

Publications (2)

Publication Number Publication Date
WO2005040828A2 WO2005040828A2 (en) 2005-05-06
WO2005040828A3 true WO2005040828A3 (en) 2005-06-16

Family

ID=34486102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011404 WO2005040828A2 (en) 2003-10-24 2004-10-12 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)

Country Status (1)

Country Link
WO (1) WO2005040828A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10339820A1 (en) * 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Use of G-protein coupled receptor, GPR49, peptides, protein and nucleic acid, for diagnosis and prognosis of tumors, also in screening for therapeutic and diagnostic agents
PL3009148T3 (en) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
CA2705509A1 (en) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
CA2841745A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
ES2697674T3 (en) 2011-11-01 2019-01-25 Bionomics Inc Procedures to block the growth of cancer stem cells
JP2014533247A (en) * 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド Antibodies and methods of treating cancer
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
EP3193935A4 (en) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015660A1 (en) * 1997-09-24 1999-04-01 Merck & Co., Inc. G-protein coupled glycoprotein hormone receptor hg38
WO1999048921A1 (en) * 1998-03-26 1999-09-30 The Board Of Trustees Of The Leland Stanford Junior University Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions
WO2000022129A1 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030235910A1 (en) * 2002-06-17 2003-12-25 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 49 expression
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015660A1 (en) * 1997-09-24 1999-04-01 Merck & Co., Inc. G-protein coupled glycoprotein hormone receptor hg38
WO1999048921A1 (en) * 1998-03-26 1999-09-30 The Board Of Trustees Of The Leland Stanford Junior University Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions
WO2000022129A1 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030235910A1 (en) * 2002-06-17 2003-12-25 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 49 expression
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAMOTO YOSHIYA ET AL: "Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations.", HEPATOLOGY, vol. 37, no. 3, March 2003 (2003-03-01), pages 528 - 533, XP008041122, ISSN: 0270-9139 *

Also Published As

Publication number Publication date
WO2005040828A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2005095972A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005040826A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 64 (gpr64)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005003762A3 (en) Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
WO2004086034A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase